Maickol Burgos- Rodriguez, NS | |
Hc 4 Box 17804, Camuy, PR 00627-9502 | |
(787) 237-6430 | |
Not Available |
Full Name | Maickol Burgos- Rodriguez |
---|---|
Gender | Male |
Speciality | Licensed Practical Nurse |
Location | Hc 4 Box 17804, Camuy, Puerto Rico |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316376874 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | 35735G (Puerto Rico) | Primary |
Mailing Address | Practice Location Address |
---|---|
Maickol Burgos- Rodriguez, NS Hc 4 Box 17804, Camuy, PR 00627-9502 Ph: (787) 237-6430 | Maickol Burgos- Rodriguez, NS Hc 4 Box 17804, Camuy, PR 00627-9502 Ph: (787) 237-6430 |
News Archive
Researchers have identified a molecule sent by fat cells to the fly brain that senses when they have had enough food and inhibits feeding, according to a study publishing March 28 in the open access journal PLOS Biology by Walton Jones of the Korea Advanced Institute of Science and Technology in Daejeon, and colleagues.
A medical device for Cystic Fibrosis (CF) sufferers which lessens their exposure to infections resulting in fewer doctors' visits, reduced antibiotic usage and shorter hospital stays, is expected to be market ready within two years.
Today's headlines include reports about a lawsuit brought by Catholic organizations against the Obama administration's contraception coverage rule and a new recommendation on PSA screening by the U.S. Preventive Services Task Force.
In response to the published study, "Dietary Supplements and Mortality Rate in Older Women," published in the Archives of Internal Medicine (a publication of the American Medical Association), the Council for Responsible Nutrition (CRN), the leading trade association representing the dietary supplement industry, issued the following two-part statement.
Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.
› Verified 3 days ago